"Meridian's Norfolk, VA (Neurology), location performs clinical studies related to disorders of the nervous system. This site explores medicines being studied for their affect on multiple sclerosis, migraines, Alzheimer's disease, seizures, epilepsy, and other neurological conditions."

During the past decade, Meridian Clinical Research conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Meridian Clinical Research" #1 sponsor was "Hoffmann-La Roche" with 2 trials, followed by "Addex Pharma S.A." with 1 trials sponsored, "Beats Medical" with 1 trials sponsored, "Biogen" with 1 trials sponsored and "Eli Lilly and Company" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Meridian Clinical Research" #1 collaborator was "Biomedical Advanced Research and Development Authority" with 1 trials as a collaborator and "Michael J. Fox Foundation for Parkinson's Research" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Meridian Clinical Research" are "Parkinson Disease" (3 trials), "Migraine" (2 trials), "Dyskinesia, Drug-Induced" (1 trials), "Dyskinesias" (1 trials) and "Episodic Migraine" (1 trials). Many other conditions were trialed in "Meridian Clinical Research" in a lesser frequency.

Most popular intervention types in "Meridian Clinical Research" are "Drug" (7 trials), "Biological" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Ocrelizumab" (2 trials), "Antihistamine" (1 trials), "BHV-3500 (zavegepant)" (1 trials) and "BIIB017 (peginterferon beta-1a)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Meridian Clinical Research" are 9 trials for "All" genders.

Currently, there are NaN active trials in "Meridian Clinical Research". 1 are not yet recruiting, 6 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Meridian Clinical Research, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Meridian Clinical Research, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".